33-047
PI 3-激酶3步式HTRF®检测
The PI 3-Kinase 3-Step HTRF Assay is a high-performance assay kit that provides a universal method for testing all Class I PI3-Kinases in a homogeneous format.
别名:
3步式HTRF检测, PI 3-激酶检测
产品名称
PI 3-激酶3步式HTRF®检测, The PI 3-Kinase 3-Step HTRF Assay is a high-performance assay kit that provides a universal method for testing all Class I PI3-Kinases in a homogeneous format.
species reactivity
human, mouse
manufacturer/tradename
HTRF®
Upstate®
technique(s)
activity assay: suitable (kinase)
NCBI accession no.
UniProt accession no.
detection method
fluorometric (HTRF)
shipped in
dry ice
Quality Level
Gene Information
human ... PIK3CA(5290)
General description
磷脂酰肌醇-4,5-二磷酸3激酶催化亚基α(PIK3CA)基因定位于人类染色体3q26.32。该基因编码IA类PI3激酶的催化亚基p110α。PI3K信号通路调节多种细胞活动和特性，包括增殖、存活、凋亡、运动和形态。PIK3CA基因的突变或过表达与各种人类实体肿瘤的发展有关，包括头颈癌或咽喉癌和卵巢癌。
Application
PI 3-激酶3步式HTRF®检测已用于测定磷脂酰肌醇3-激酶(PI3K)δ抑制剂（如MSD-496486311、MSD126796721、ideelalisib和duvelisib）对PI3K α、β、γ和δ异构体的体外抑制效力。
Biochem/physiol Actions
靶标亚家族：PI3K/PI4K
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
Other Notes
4X反应缓冲液
PIP2（底物；1mM储备液）
DM A反应缓冲液
DM B反应缓冲液
DM C反应缓冲液
BPIP3
终止试剂
PIP2（底物；1mM储备液）
DM A反应缓冲液
DM B反应缓冲液
DM C反应缓冲液
BPIP3
终止试剂
研究类别
细胞凋亡 & 癌症
研究子类别
肿瘤学
细胞凋亡 & 癌症
研究子类别
肿瘤学
Packaging
试剂盒容量：10,000孔
Preparation Note
在-70°C下可保存12个月
Legal Information
HTRF is a registered trademark of Cis Bio International
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Andreas G Bader et al.
Nature reviews. Cancer, 5(12), 921-929 (2005-12-13)
There have long been indications of a role for PI3K (phosphatidylinositol 3-kinase) in cancer pathogenesis. Experimental data document a requirement for deregulation of both transcription and translation in PI3K-mediated oncogenic transformation. The recent discoveries of cancer-specific mutations in PIK3CA, the
Robbie L McLeod et al.
The Journal of pharmacology and experimental therapeutics, 369(2), 223-233 (2019-02-26)
We leveraged a clinical pharmacokinetic (PK)/pharmacodynamics (PD)/efficacy relationship established with an oral phosphatidylinositol 3-kinase (PI3K)δ inhibitor (Idelalisib) in a nasal allergen challenge study to determine whether a comparable PK/PD/efficacy relationship with PI3Kδ inhibitors was observed in preclinical respiratory models of
Wanglong Qiu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 12(5), 1441-1446 (2006-03-15)
Recent studies have reported high frequencies of somatic mutations in the phosphoinositide-3-kinase catalytic alpha (PIK3CA) gene in several human solid tumors. Although gene amplifications of PIK3CA have been reported in head and neck squamous cell carcinoma (HNSCC), small mutation of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持